Alkermes' Alixorexton Receives Orphan Drug Designations in US & EU for Hypersomnia & Narcolepsy
ALKS sits 77% above its 52-week low of $25.165.
Summary
Alkermes announced that its drug candidate alixorexton received Orphan Drug Designations from the FDA and European Commission for rare sleep disorders, providing key regulatory and commercial advantages.
Key Events · Product Development and Regulatory · ALKS
-
Orphan Drug Designation for Idiopathic Hypersomnia
The U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to alixorexton for the treatment of idiopathic hypersomnia.
-
Orphan Drug Designation for Narcolepsy
The European Commission has granted Orphan Drug Designation to alixorexton for the treatment of narcolepsy.
-
Regulatory Incentives and Market Exclusivity
These designations provide development incentives including tax credits, exemptions from certain FDA application fees, and potential market exclusivity (7 years in the U.S., 10 years in the EU) if the drug is approved.
-
Late-Stage Clinical Development
Alixorexton is currently being evaluated in Phase 3 Brilliance Studies for narcolepsy type 1 and type 2, and in a Phase 2 Vibrance-3 study for idiopathic hypersomnia.
Analysis · ALKS · Life Sciences
Alkermes' investigational drug, alixorexton, has received Orphan Drug Designations from the U.S. FDA for idiopathic hypersomnia and from the European Commission for narcolepsy. These designations provide significant development incentives, such as tax credits and reduced regulatory fees, and potential market exclusivity upon approval, enhancing the drug's commercial prospects and de-risking its path through late-stage clinical trials.
At the time of this filing, ALKS was trading at $44.60 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $7.4B. The 52-week trading range was $25.17 to $45.76. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.